secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001193125-22-301902
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca (ERAS) prices $100M public offering and issues $80M stock to Novartis under license
--------------------------------------------------------------------------------

- Underwritten offering of 15,384,616 shares at $6.50/share; net proceeds ~$94.7M; expected close Dec 13, 2022.
- Private placement to Novartis of 12,307,692 shares at $6.50/share as partial consideration for exclusive license agreement.
- J.P. Morgan and Goldman Sachs are joint book-running managers for the public offering.
- Proceeds to fund R&D of RAS/MAPK pathway programs and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312522301902/0001193125-22-301902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312522301902/d435484d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer